var data={"title":"All-trans retinoic acid (systemic tretinoin): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">All-trans retinoic acid (systemic tretinoin): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7091?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=all-trans-retinoic-acid-systemic-tretinoin-patient-drug-information\" class=\"drug drug_patient\">see &quot;All-trans retinoic acid (systemic tretinoin): Patient drug information&quot;</a> and <a href=\"topic.htm?path=all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;All-trans retinoic acid (systemic tretinoin): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708896\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients with acute promyelocytic leukemia (APL) are at high risk in general and can have severe adverse reactions to tretinoin. Therefore, administer tretinoin only to patients with APL under the strict supervision of a health care provider who is experienced in the management of patients with acute leukemia, and in a facility with laboratory and supportive services sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity, including respiratory compromise. Use of tretinoin requires that the health care provider conclude the possible benefit to the patient outweighs the following known adverse reactions in therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">APL differentiation syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Approximately 25% of patients with APL treated with tretinoin have experienced the retinoic acid-APL (RA-APL) syndrome, characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multiorgan failure. This syndrome occasionally has been accompanied by impaired myocardial contractility and episodic hypotension. It has been observed with or without concomitant leukocytosis. Endotracheal intubation and mechanical ventilation have been required in some cases due to progressive hypoxemia, and several patients have expired with multiorgan failure. The syndrome generally occurs during the first month of treatment, with some cases reported following the first dose of tretinoin.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The management of the syndrome has not been defined rigorously, but high-dose steroids given at the first suspicion of the RA-APL syndrome appear to reduce morbidity and mortality. At the first signs suggestive of the syndrome (eg, unexplained fever, dyspnea and/or weight gain, abnormal chest auscultatory findings, radiographic abnormalities), initiate high-dose steroids (dexamethasone 10 mg intravenous [IV] administered every 12 hours for 3 days or until the resolution of symptoms) immediately, irrespective of the leukocyte count. The majority of patients do not require termination of tretinoin therapy during treatment of the RA-APL syndrome. However, in cases of moderate and severe RA-APL syndrome, consider temporary interruption of tretinoin therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Leukocytosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">During tretinoin treatment, approximately 40% of patients will develop rapidly evolving leukocytosis. Patients who present with high white blood cell (WBC) at diagnosis (more than 5 &times; 10<sup>9</sup>/L) have an increased risk of a further rapid increase in WBC counts. Rapidly evolving leukocytosis is associated with a higher risk of life-threatening complications.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If signs and symptoms of the RA-APL syndrome are present together with leukocytosis, immediately initiate treatment with high-dose steroids. Some investigators routinely add chemotherapy to tretinoin treatment in the case of patients presenting with a WBC count of more than 5 &times; 10<sup>9</sup>/L or in the case of a rapid increase in WBC count for patients leukopenic at start of treatment, and have reported a lower incidence of the RA-APL syndrome. Consider adding full-dose chemotherapy (including an anthracycline if not contraindicated) to tretinoin therapy on day 1 or 2 for patients presenting with a WBC count of more than 5 &times; 10<sup>9</sup>/L; immediately add for patients presenting with a WBC count of less than 5 x 10<sup>9</sup>/L, if the WBC count reaches greater than or equal to 6 &times; 10<sup>9</sup>/L by day 5, greater than or equal to 10 &times; 10<sup>9</sup>/L by day 10, or greater than or equal to 15 &times; 10<sup>9</sup>/L by day 28.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Pregnancy (Category D): There is a high risk that a severely deformed infant will result if tretinoin is administered during pregnancy. If, nonetheless, it is determined that tretinoin represents the best available treatment for a pregnant woman or a woman of childbearing potential, it must be assured that the patient has received full information and warnings of the risk to the fetus if she were to be pregnant and of the risk of possible contraception failure. Instruct the patient to use 2 reliable forms of contraception simultaneously during therapy and for 1 month following discontinuation of therapy, and emphasize the need for using dual contraception, unless abstinence is the chosen method.</p>\n        <p style=\"text-indent:-4em;margin-left:4em;\">Within 1 week prior to the institution of tretinoin therapy, collect blood or urine from the patient for a serum or urine pregnancy test with a sensitivity of at least 50 milliunits/mL. When possible, delay tretinoin therapy until a negative result from this test is obtained. When a delay is not possible, place the patient on 2 reliable forms of contraception. Repeat pregnancy testing and contraception counseling monthly throughout the period of tretinoin treatment.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230427\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vesanoid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230446\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Retinoic Acid Derivative;</li>\n      <li>\n        Retinoic Acid Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230429\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Induction treatment of APL with tretinoin should be initiated early; discontinue if pending cytogenetic analysis does not confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acute promyelocytic leukemia (APL):</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Remission induction (manufacturer&rsquo;s labeling): </i> 45 mg/m<sup>2</sup>/day in 2 equally divided doses until documentation of complete remission (CR); discontinue 30 days after CR or after 90 days of treatment, whichever occurs first</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Remission induction (in combination with an anthracycline &plusmn; cytarabine): </i> 45 mg/m<sup>2</sup>/day in 2 equally divided doses until complete remission or 90 days (Powell 2010) or until complete hematologic remission (Ades 2008; Sanz 2008; Sanz 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Remission induction (in combination with arsenic trioxide; off-label combination):</i> 45 mg/m<sup>2</sup>/day in 2 equally divided doses until &lt;5% blasts in marrow and no abnormal promyelocytes or up to 85 days (Estey 2006; Ravandi 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Consolidation therapy (off-label use):</i> 45 mg/m<sup>2</sup>/day in 2 equally divided doses for 15 days each month for 3 months (in combination with chemotherapy) (Lo-Coco 2010; Sanz 2010) <b>or</b> 45 mg/m<sup>2</sup>/day for 14 days every 4 weeks for 7 cycles (in combination with arsenic trioxide) (Ravandi 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Maintenance therapy, intermediate- and high-risk patients (off-label use): </i>  45 mg/m<sup>2</sup>/day in 2 equally divided doses for 15 days every 3 months for 2 years (Ades 2008; Sanz 2004) <b>or</b> 45 mg/m<sup>2</sup>/day in 2 equally divided doses for 7 days every other week for 1 year (Powell 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230440\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;All-trans retinoic acid (systemic tretinoin): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\"> <b>Note:</b> Induction treatment of APL with tretinoin should be initiated early; discontinue if pending cytogenetic analysis does not confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute promyelocytic leukemia (APL):</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Remission induction (manufacturer&rsquo;s labeling): </i>45 mg/m<sup>2</sup>/day in 2 equally divided doses until documentation of complete remission (CR); discontinue 30 days after CR or after 90 days of treatment, whichever occurs first</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Remission induction (in combination with an anthracycline; off-label dose):</i> 25 mg/m<sup>2</sup>/day in 2 equally divided doses until complete remission or 90 days (Ortega 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Consolidation therapy, intermediate- and high-risk patients (off-label use):</i> 25 mg/m<sup>2</sup>/day in 2 equally divided doses for 15 days each month for 3 months (Ortega 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Maintenance therapy, intermediate- and high-risk patients (off-label use):</i> 25 mg/m<sup>2</sup>/day in 2 equally divided doses for 15 days every 3 months for 2 years (Ortega 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230430\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16336699\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16336700\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771485\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">APL differentiation syndrome: Initiate dexamethasone 10 mg IV every 12 hours for 3 to 5 days; consider interrupting tretinoin until resolution of hypoxia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Liver function tests &gt;5 times the upper limit of normal: Consider temporarily withholding treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230404\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230389\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230407\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer orally with a meal; do not crush capsules.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tretinoin has also been administered sublingually by squeezing the capsule contents beneath the tongue (Kueh 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Low plasma concentrations have been reported when tretinoin has been administered through a feeding tube, although patient-specific impaired absorption or a lack of excipient (eg, soybean oil) may have been a contributing factor (Takitani 2004). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132846\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230405\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute promyelocytic leukemia (remission induction):</b> Induction of remission in patients with acute promyelocytic leukemia, French American British (FAB) classification M3 (including the M3 variant) characterized by t(15;17) translocation and/or PML/RAR&alpha; gene presence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744924\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute promyelocytic leukemia (consolidation therapy); Acute promyelocytic leukemia (maintenance therapy in intermediate- and high-risk patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16254058\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tretinoin may be confused with ISOtretinoin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vesanoid may be confused with  VESIcare</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tretinoin (which is also called all-<i>trans</i> retinoic acid, or ATRA) may be confused with isotretinoin; while both products may have uses in cancer treatment, they are <b>not</b> interchangeable.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230396\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Most patients will experience drug-related toxicity, especially headache, fever, weakness and fatigue. These are seldom permanent or irreversible and do not typically require therapy interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (52%), chest discomfort (32%), edema (29%), cardiac arrhythmia (23%), flushing (23%), hypotension (14%), hypertension (11%), localized phlebitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (86%), malaise (66%), shivering (63%), pain (37%), dizziness (20%), anxiety (17%), paresthesia (17%), depression (14%), insomnia (14%), confusion (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic:  Xeroderma (&le;77%), skin rash (54%), diaphoresis (20%), pruritus (20%), alopecia (14%), skin changes (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercholesterolemia (&le;60%), hypertriglyceridemia (&le;60%), weight gain (23%), weight loss (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dry mucous membranes (&le;77%), nausea (&le;57%), vomiting (&le;57%), gastrointestinal hemorrhage (34%), abdominal pain (31%), mucositis (26%), diarrhea (23%), anorexia (17%), constipation (17%), dyspepsia (14%), abdominal distention (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (60%), leukocytosis (40%), disseminated intravascular coagulation (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (50% to 60%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (58%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Ostealgia (77%), APL differentiation syndrome (&le;25%), myalgia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye disease (17%), visual disturbance (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (23%; ear fullness)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory complaint (63%), dyspnea (60%), respiratory insufficiency (26%), pleural effusion (20%), pneumonia (14%), rales (14%), wheezing (expiratory: 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (83%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure (6%), facial edema (6%), cardiomegaly (3%), cardiomyopathy (3%), cerebrovascular accident (3%), heart murmur (3%), ischemia (3%), myocardial infarction (3%), myocarditis (3%), pericarditis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Agitation (9%), cerebral hemorrhage (9%), flank pain (9%), intracranial hypertension (9%), hallucination (6%), abnormal gait (3%), agnosia (3%), aphasia (3%), asterixis (3%), ataxia (3%), brain disease (3%), cerebral edema (cerebellar: 3%), central nervous system depression (3%), coma (3%), dementia (3%), drowsiness (3%), dysarthria (3%), facial paralysis (3%), forgetfulness (3%), hemiplegia (3%), hyporeflexia (3%), hypothermia (3%), loss of consciousness (3%), seizure (3%), speech disturbance (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Cellulitis (8%), pallor (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Disturbance in fluid balance (6%), acidosis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal ulcer (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (9%), benign prostatic hypertrophy (3%), urinary frequency (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphatic disease (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatosplenomegaly (9%), ascites (3%), hepatitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local inflammation (bone: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Lower extremity weakness (3%), myelopathy (3%), tremor (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Decreased visual acuity (6%), decreased pupillary reflex (3%), visual field defect (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Hearing loss (6%; may be irreversible)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure (3%), renal tubular necrosis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Lower respiratory signs and symptoms (9%), pulmonary infiltrates (6%), asthma (3%), laryngeal edema (3%), pulmonary hypertension (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Arterial thrombosis, basophilia, erythema nodosum, histamine release (hyperhistaminemia), hypercalcemia, hypersensitivity angiitis, myositis, pancreatitis, pseudotumor cerebri, renal infarction, Sweet's syndrome, thrombocythemia, ulcer (genital), venous thrombosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230410\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tretinoin, other retinoids, parabens, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230393\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; APL differentiation syndrome: <b>[US  Boxed Warning]: About 25% of patients with APL treated with tretinoin have experienced APL differentiation syndrome (formerly called retinoic-acid-APL [RA-APL] syndrome), which is characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, and pleural or pericardial effusions, edema, and hepatic, renal, and/or multiorgan failure. </b> <b>The syndrome may be accompanied by impaired myocardial contractility and episodic hypotension. It has been observed with or without concomitant leukocytosis. Intubation and mechanical ventilation have been required in some cases due to progressive hypoxemia; fatalities due to multiorgan failure have occurred. The syndrome generally occurs during the first month of treatment, with some cases reported following the first dose. Management has not been defined, although high-dose steroids given at the first suspicion appear to reduce morbidity and mortality. Regardless of the leukocyte count, at the first signs suggestive of APL differentiation syndrome (eg, unexplained fever, dyspnea and/or weight gain, abnormal chest auscultatory findings, radiographic abnormalities), immediately initiate corticosteroid therapy with dexamethasone 10 mg IV every 12 hours for 3 to 5 days (or until the symptoms resolve); taper off over 2 weeks. Most patients do not require termination of tretinoin therapy during treatment of the APL differentiation syndrome.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Venous thrombosis and MI have been reported in patient without risk factors for thrombosis or MI. The risk for thrombosis (arterial and venous) is increased during the first month of treatment. Use with caution with antifibrinolytic agents; thrombotic complications have been reported (rarely) with concomitant use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: May cause headache, malaise, and/or dizziness; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Leukocytosis: <b>[US Boxed Warning]: During treatment, ~40% of patients will develop rapidly evolving leukocytosis. Patients who present with a high WBC at diagnosis (&gt;5,000/mm<sup>3</sup>) are at increased risk of further rapid increase in WBC counts. Rapidly evolving leukocytosis is associated with a higher risk of life-threatening complications. Initiate treatment with high-dose corticosteroids immediately if signs and symptoms of APL differentiation syndrome are present with leukocytosis. Chemotherapy may be added to tretinoin treatment in patients presenting with a WBC count &gt;5,000/mm<sup>3</sup> or for a rapid WBC increase in patients leukopenic at start of treatment (may result in a lower incidence of APL differentiation syndrome). Consider adding full-dose chemotherapy (including an anthracycline if not contraindicated) to tretinoin therapy on day 1 or 2 for patients presenting with a WBC count &gt;5,000/mm<sup>3</sup>; immediately add for patients presenting with a WBC count &lt;5,000/mm<sup>3</sup> if the WBC count reaches &ge;6,000/mm<sup>3</sup> by day 5, &ge;10,000/mm<sup>3</sup> by day 10, or &ge;15,000/mm<sup>3</sup> by day 28.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lipid effects: Up to 60% of patients experienced hypercholesterolemia or hypertriglyceridemia, which were reversible upon completion of treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Liver function test abnormalities: Elevated liver function test results occur in 50% to 60% of patients during treatment. Carefully monitor liver function test results during treatment and give consideration to a temporary withdrawal of tretinoin if test results reach &gt;5 times the upper limit of normal. Most liver function test abnormalities will resolve without interruption of treatment or after therapy completion. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pseudotumor cerebri: Retinoids have been associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect (eg, tetracyclines) may increase risk. Early signs and symptoms include papilledema, headache, nausea, vomiting, visual disturbances, intracranial noises, or pulsate tinnitus. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; APL: Tretinoin treatment for APL should be initiated early, discontinue if pending cytogenetic analysis does not confirm APL by t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein (caused by translocation of the promyelocytic [PML] gene on chromosome 15 and retinoic acid receptor [RAR] alpha gene on chromosome 17). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[US Boxed Warning]: High risk of teratogenicity; if treatment with tretinoin is required in women of childbearing potential, two reliable forms of contraception should be used during and for 1 month after discontinuation of treatment, unless abstinence is the chosen method. Within 1 week prior to starting therapy, serum or urine pregnancy test (sensitivity at least 50 milliunits/mL) should be collected. If possible, delay therapy until results are available. Repeat pregnancy testing and contraception counseling monthly throughout the period of treatment.</b> Microdosed progesterone products (&ldquo;minipill&rdquo;) may provide inadequate pregnancy protection. Repeat pregnancy testing and contraception counseling monthly throughout the period of treatment. If possible, initiation of treatment with tretinoin should be delayed until negative pregnancy test result is confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Product interchange: Tretinoin (which is also known as all-<i>trans</i> retinoic acid, or ATRA) and isotretinoin may be confused, while both products may be used in cancer treatment, they are <b>not</b> interchangeable; verify product prior to dispensing and administration to prevent medication errors. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b> [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. Patients with APL are at high risk and can have severe adverse reactions to tretinoin. Administer tretinoin only to patients with APL under the close supervision of a provider who is experienced in the management of patients with acute leukemia, and in a facility with laboratory and supportive services for appropriate monitoring. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230441\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2C8 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak); <b>Induces</b> CYP2E1 (weak/moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230398\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9262&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifibrinolytic Agents: Tretinoin (Systemic) may enhance the thrombogenic effect of Antifibrinolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin A: May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230422\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Absorption of retinoids has been shown to be enhanced when taken with food. Management: Administer with a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230400\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230413\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. <b>[US Boxed Warning]: High risk of teratogenicity; if treatment with tretinoin is required in women of childbearing potential, two reliable forms of contraception should be used simultaneously during and for 1 month after discontinuation of treatment, unless abstinence is the chosen method. Within 1 week prior to starting therapy, serum or urine pregnancy test (sensitivity at least 50 milliunits/mL) should be collected. If possible, delay therapy until results are available. Repeat pregnancy testing and contraception counseling monthly throughout the period of treatment.</b> Contraception must be used even when there is a history of infertility or menopause, unless a hysterectomy has been performed. Tretinoin was detected in the serum of a neonate at birth following maternal use of standard doses during pregnancy (Takitani 2005). Use in humans for the treatment of acute promyelocytic leukemia (APL) is limited and exposure occurred after the first trimester in most cases (Valappil 2007). However, major fetal abnormalities and spontaneous abortions have been reported with other retinoids; some of these abnormalities were fatal. If the clinical condition of a patient presenting with APL during pregnancy warrants immediate treatment, tretinoin use should be avoided in the first trimester; treatment with tretinoin may be considered in the second and third trimester with careful fetal monitoring, including cardiac monitoring (Sanz 2009).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16336698\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tretinoin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be discontinued prior to treatment initiation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230414\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The absorption of retinoids (as a class) is enhanced when taken with food. Capsule contains soybean oil. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230402\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Bone marrow cytology to confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein (do not withhold treatment initiation for results); monitor CBC with differential, coagulation profile, liver function test results, and triglyceride and cholesterol levels frequently; monitor closely for signs of APL differentiation syndrome (eg, monitor volume status, pulmonary status, temperature, respiration)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230392\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Tretinoin appears to bind one or more nuclear receptors and decreases proliferation and induces differentiation of APL cells; initially produces maturation of primitive promyelocytes and repopulates the marrow and peripheral blood with normal hematopoietic cells to achieve complete remission </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230409\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">\n      <b>Note: </b>Reported pediatric values similar to adult (Smith 1992; Takitani 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;95%, predominantly to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP; primary metabolite: 4-oxo-all-<i>trans</i>-retinoic acid; displays autometabolism </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Parent drug: 0.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (63%); feces (30%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324024\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tretinoin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $3,735.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230415\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Reticap-5 (BD);</li>\n      <li>Vesanoid (AE, AR, AT, AU, BE, BH, BR, CH, CN, CO, CR, CY, CZ, DE, DO, ES, FI, FR, GB, GT, HK, HN, HR, IE, IL, IT, JO, JP, KR, KW, LK, MX, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, QA, SI, SK, SV, TH, TW, VE, VN);</li>\n      <li>Vesanoyid (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17975017\"></a>Ad&egrave;s L, Sanz MA, Chevret S, et al, &ldquo;Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison of French-Belgian-Swiss and PETHEMA Results,&rdquo; <i>Blood</i>, 2008, 111(3):1078-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/17975017/pubmed\" target=\"_blank\" id=\"17975017\">17975017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bargetzi MJ, Tichelli A, Gratwohl A, et al, &ldquo;Oral All-Transretinoic Acid Administration in Intubated Patients With Acute Promyelocytic Leukemia,&rdquo; <i>Schweiz Med Wochenschr</i>, 1996, 126(45):1944-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/8946598/pubmed\" target=\"_blank\" id=\"8946598\">8946598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen GQ, Shen ZX, Wu F, et al, &ldquo;Pharmacokinetics and Efficacy of Low-Dose All-<i>trans</i> Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia,&rdquo; <i>Leukemia</i>, 1996, 10(5):825-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/8656678/pubmed\" target=\"_blank\" id=\"8656678\">8656678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estey E, Garcia-Manero G, Ferrajoli A, et al, &quot;Use of All-<i>Trans</i> Retinoic Acid Plus Arsenic Trioxide as an Alternative to Chemotherapy in Untreated Acute Promyelocytic Leukemia,&quot; <i>Blood</i>, 2006, 107(9):3469-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/16373661/pubmed\" target=\"_blank\" id=\"16373661\">16373661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gregory J, Kim H, Alonzo T, et al, &ldquo;Treatment of Children With Acute Promyelocytic Leukemia: Results of the First North American Intergroup Trial INT0129,&rdquo; <i>Pediatr Blood Cancer</i>, 2009, 53(6):1005-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/19743516/pubmed\" target=\"_blank\" id=\"19743516\">19743516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kueh YK, Liew PP, Ho PC, et al, &ldquo;Sublingual Administration of All-<i>Trans</i>-Retinoic Acid to a Comatose Patient With Acute Promyelocytic Leukemia,&rdquo; <i>Ann Pharmacother</i>, 1999, 33(4):503-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/10332546/pubmed\" target=\"_blank\" id=\"10332546\">10332546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kurzrock R, Estey E, and Talpaz M, &ldquo;All-<i>trans</i> Retinoic Acid: Tolerance and Biologic Effects in Myelodysplastic Syndrome,&rdquo; <i>J Clin Oncol</i>, 1993, 11(8):1489-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/8336187/pubmed\" target=\"_blank\" id=\"8336187\">8336187</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazzarino M, Regazzi MB, and Corso A, &ldquo;Clinical Relevance of All-<i>trans</i> Retinoic Acid Pharmacokinetics and Its Modulation in Acute Promyelocytic Leukemia,&rdquo; <i>Leuk Lymphoma</i>, 1996, 23(5-6):539-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/9031084/pubmed\" target=\"_blank\" id=\"9031084\">9031084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20644121\"></a>Lo Coco F, Avvisati G, Vignetti M, et al, &ldquo;Front-Line Treatment of Acute Promyelocytic Leukemia With AIDA Induction Followed by Risk-Adapted Consolidation for Adults Younger Than 61 Years: Results of the AIDA-2000 Trial of the GIMEMA Group,&rdquo; <i>Blood</i>, 2010, 116(17):3171-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/20644121/pubmed\" target=\"_blank\" id=\"20644121\">20644121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montesinos P, Bergua JM, Vellenga E, et al, &ldquo;Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Treated with All-<i>Trans</i> Retinoic Acid and Anthracycline Chemotherapy: Characteristics, Outcomes, and Prognostic Factors,&rdquo; <i>Blood</i>, 2009, 113(4):775-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/18945964/pubmed\" target=\"_blank\" id=\"18945964\">18945964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muindi JR, Frankel SR, Huselton C, et al, &ldquo;Clinical Pharmacology of Oral All-<i>trans</i> Retinoic Acid in Patients With Acute Promyelocytic Leukemia,&rdquo; <i>Cancer Res</i>, 1992, 52(8):2138-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/1559217/pubmed\" target=\"_blank\" id=\"1559217\">1559217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16234524\"></a>Ortega JJ, Madero L, Martin G, et al, &ldquo;Treatment With All-<i>Trans</i> Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7632-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/16234524/pubmed\" target=\"_blank\" id=\"16234524\">16234524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20705755\"></a>Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo; <i>Blood</i>, 2010, 116(19):3751-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/20705755/pubmed\" target=\"_blank\" id=\"20705755\">20705755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19075265\"></a>Ravandi F, Estey E, Jones D, et al, &quot;Effective Treatment of Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin,&quot; <i>J Clin Oncol</i>, 2009, 27(4):504-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/19075265/pubmed\" target=\"_blank\" id=\"19075265\">19075265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MA, Grimwade D, Tallman MS, et al, &ldquo;Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,&rdquo; <i>Blood</i>, 2009, 113(9):1875-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/18812465/pubmed\" target=\"_blank\" id=\"18812465\">18812465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14576047\"></a>Sanz MA, Martin G, Gonzalez M, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,&rdquo; <i>Blood</i>, 2004, 103(4):1237-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/14576047/pubmed\" target=\"_blank\" id=\"14576047\">14576047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20393132\"></a>Sanz MA, Montesinos P, Ray&oacute;n C, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia Based on all-trans Retinoic Acid and Anthracycline With Addition of Cytarabine in Consolidation Therapy for High-Risk Patients: Further Improvements in Treatment Outcome,&rdquo; <i>Blood</i>, 2010, 115(25):5137-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/20393132/pubmed\" target=\"_blank\" id=\"20393132\">20393132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MA, Montesinos P, Vellenga E, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid and Anthracycline Monochemotherapy: Long-Term Outcome of the LPA 99 Multicenter Study by the PETHEMA Group,&rdquo; <i>Blood</i>, 2008, 112(8):3130-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/18664623/pubmed\" target=\"_blank\" id=\"18664623\">18664623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw PJ, Atkins MC, Nath CE, et al, &rdquo;ATRA Administration in the Critically Ill Patient,&rdquo; <i>Leukemia</i>, 1995, 9(7):1288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/7630206/pubmed\" target=\"_blank\" id=\"7630206\">7630206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith MA, Adamson PC, Balis FM, et al, &ldquo;Phase I and Pharmacokinetic Evaluation of All-<i>trans</i>-Retinoic Acid in Pediatric Patients With Cancer,&rdquo; <i>J Clin Oncol</i>, 1992, 10(11):1666-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/1403049/pubmed\" target=\"_blank\" id=\"1403049\">1403049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takitani K, Hino N, Terada Y, et al. Plasma all-trans retinoic acid level in neonates of mothers with acute promyelocytic leukemia. <i>Acta Haematol</i>. 2005;114(3):167-169.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takitani K, Nakao Y, Kosada Y, et al, &ldquo;Low Plasma Levels of All-<i>Trans</i> Retinoic Acid After Feeding Tube Administration for Acute Promyelocytic Leukemia,&rdquo; <i>Am J Hematol</i>, 2004, 76(1):97-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/15114613/pubmed\" target=\"_blank\" id=\"15114613\">15114613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Testi AM, Biondi A, Lo Coco F, et al, &ldquo;GIMEMA_AIEOPAIDA Protocol for the Treatment of Newly Diagnosed Acute Promyelocutic Leukemia (APL) in Children,&rdquo; <i>Blood</i>, 2005, 106(2): 447-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/15677559/pubmed\" target=\"_blank\" id=\"15677559\">15677559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tretinoin [prescribing information]. Columbus, OH: American Health Packaging; February 2013</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tretinoin [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies, Inc.; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tretinoin [prescribing information]. Sellersville, PA: Teva Pharmaceuticals; November 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valappil S, Kurkar M, Howell R. Outcome of pregnancy in women treated with all-trans retinoic acid; a case report and review of literature. <i>Hematology</i>. 2007;12(5):415-418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information/abstract-text/17852449/pubmed\" target=\"_blank\" id=\"17852449\">17852449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vesanoid (tretinoin) [prescribing information]. Nutley, NJ: Roche Laboratories; October 2004.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9262 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708896\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F230427\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F230446\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F230429\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F230440\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F230430\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16336699\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16336700\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F8771485\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F230404\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F230389\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F230407\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132846\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F230405\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744924\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16254058\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F230396\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F230410\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F230393\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F230441\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F230398\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F230422\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F230400\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F230413\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16336698\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F230414\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F230402\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F230392\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F230409\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324024\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F230415\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9262|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=all-trans-retinoic-acid-systemic-tretinoin-patient-drug-information\" class=\"drug drug_patient\">All-trans retinoic acid (systemic tretinoin): Patient drug information</a></li><li><a href=\"topic.htm?path=all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information\" class=\"drug drug_pediatric\">All-trans retinoic acid (systemic tretinoin): Pediatric drug information</a></li></ul></div></div>","javascript":null}